Effect of spironolactone on cardiovascular morbidity and mortality in patients with hypertension and glucose metabolism disorders (ESCAM): a study protocol for a pragmatic randomised controlled trial
Introduction Hypertension combined with diabetes and hypokalemia is more likely to develop hyperaldosteronism and is at higher risk of cardiovascular events. There is evidence that activation of aldosterone and mineralocorticoid receptors may play a significant role in the occurrence of cardiovascul...
Main Authors: | Nanfang Li, Lin Wang, Qin Luo, Jing Hong, Mengyue Lin, Mulalibieke Heizhati, Jina Yili, Xiaoguang Yao, Qing Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/10/11/e038694.full |
Similar Items
-
Chinese Visceral Adiposity Index Is Associated With Incident Renal Damage in Patients With Hypertension and Abnormal Glucose Metabolism: A Longitudinal Study
by: Mengyue Lin, et al.
Published: (2022-07-01) -
Higher plasma renin activity is associated with increased kidney damage risk in patients with hypertension and glucose metabolic disorders
by: Mengyue Lin, et al.
Published: (2022-06-01) -
Higher plasma aldosterone is associated with increased risk of cardiovascular events in hypertensive patients with suspected OSA: UROSAH data
by: Lin Gan, et al.
Published: (2022-10-01) -
A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes
by: Mengyue Lin, et al.
Published: (2021-05-01) -
The association between blood pressure control and long-term cardiovascular outcomes in Hypertension coexistent with obstructive sleep apnea
by: Xiaoguang Yao, et al.
Published: (2023-11-01)